James A Kaye
Overview
Explore the profile of James A Kaye including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
1611
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Djibo D, Margulis A, McMahill-Walraven C, Saltus C, Shuminski P, Kaye J, et al.
Pharmacoepidemiol Drug Saf
. 2023 Sep;
33(1):e5690.
PMID: 37669770
Purpose: To evaluate the positive predictive value (PPV) of an endometrial cancer case finding algorithm using International Classification of Disease 10th revision Clinical Modification (ICD-10-CM) diagnosis codes from US insurance...
2.
Davis K, Gutierrez B, Zyczynski T, Kaye J
J Health Econ Outcomes Res
. 2023 Sep;
2(2):119-130.
PMID: 37663582
Docetaxel has been a standard of care for castration-resistant prostate cancer (CRPC) in the United States since 2004, yet little has been reported on its patterns of use in routine...
3.
Hicks B, Kaye J, Azoulay L, Kristensen K, Habel L, Pottegard A
Ann Epidemiol
. 2023 May;
84:25-32.
PMID: 37169040
Purpose: With the increasing utilization of medications worldwide, coupled with the increasing availability of long-term data, there is a growing opportunity and need for robust studies evaluating drug-cancer associations. One...
4.
Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the USA
Bhandari N, Hess L, Parikh R, Sireci A, Krein P, Kaye J
Per Med
. 2023 Feb;
20(2):131-142.
PMID: 36749615
To describe real-world testing patterns for in US patients with advanced/metastatic medullary thyroid cancer and determine consistency of real-world testing practices with national guidelines. The authors performed a retrospective medical...
5.
Johannes C, Saltus C, Kaye J, Calingaert B, Kaplan S, Gordon M, et al.
Pharmacoepidemiol Drug Saf
. 2022 Feb;
31(6):643-651.
PMID: 35224798
Purpose: Compare the risk of melanoma between initiators of rasagiline or other antiparkinsonian drugs (APDs) in a Parkinson's disease (PD) population. Methods: A retrospective cohort study was conducted in the...
6.
Parikh R, Hess L, Esterberg E, Bhandari N, Kaye J
Thyroid Res
. 2022 Feb;
15(1):2.
PMID: 35151352
Background: Medullary thyroid cancer (MTC) accounts for approximately 1.6% of new cases of thyroid cancer. The objective of this study was to describe patient characteristics, biomarker testing, treatment patterns, and...
7.
Arana A, Pottegard A, Kuiper J, Booth H, Reutfors J, Calingaert B, et al.
Clin Epidemiol
. 2022 Jan;
13:1141-1153.
PMID: 35002327
Purpose: Evidence is insufficient to infer whether topical calcineurin inhibitors (TCIs; tacrolimus and pimecrolimus) cause malignancy. The study objective was to estimate the long-term risk of skin cancer and lymphoma...
8.
Fortuny J, Plana E, Kaye J
Leuk Lymphoma
. 2021 Dec;
63(2):291-303.
PMID: 34963420
We conducted a case-control study of patients from the Clinical Practice Research Datalink in the United Kingdom to describe the trajectories of serum lipid in the years before a diagnosis...
9.
Boeri M, Purdum A, Sutphin J, Hauber B, Kaye J
Future Oncol
. 2021 Sep;
17(34):4697-4709.
PMID: 34581197
We evaluated physicians' willingness to trade-off benefits, risks and time to infusion for CAR T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. In a discrete-choice experiment survey, 150...
10.
Goyal R, Jain P, Nagar S, Le H, Kabadi S, Davis K, et al.
Leuk Lymphoma
. 2021 May;
62(6):1325-1334.
PMID: 33966583
Most data on overall survival (OS) and adverse events (AEs) in patients with mantle cell lymphoma (MCL) are from controlled trials; therefore, in this population-based study, we retrospectively assessed treatment...